MapLight Therapeutics, a biotech developing treatments for central nervous system disorders, aims to raise about $250 million in its IPO, at a $700 million-plus valuation.
Why it matters: MapLight's offering would be only the second biotech IPO since February as the industry grapples with financial and policy headwinds.
